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Introduction
With the increasing potential for targeted therapies in
autoinflammatory diseases, there is the need for validated
and standardized assessment tools which can be used to
evaluate the level of disease activity and response to ther-
apy.An international collaboration, initiated by Assistance
Publique-Hôpitaux de Paris (APHP) in association with
the Paediatric Rheumatology International Trials Organi-
zation (PRINTO at www.printo.it) and supported by the
EUROFEVER and EUROTRAPS networks, has previously
designed the content and the preliminary scoring of an
Auto-Inflammatory Disease Activity Index (AIDAI).
Objectives
To validate the AIDAI score in the four major hereditary
recurrent fever syndromes (HRFs): familial Mediterranean
fever (FMF), mevalonate kinase deficiency (MKD), tumor
necrosis factor receptor-associated periodic syndrome
(TRAPS), and cryopyrin-associated periodic syndromes
(CAPS).
Methods
In 2010, an international collaboration established the
content of a disease activity tool for HRFs. Patients com-
pleted a one-month prospective diary with 12 yes/no
(dichotomous) items prior to a clinical appointment dur-
ing which their physician assessed their disease activity
by a questionnaire. Eight international experts in auto-
inflammatory diseases evaluated patient’s disease activity
by a blinded web-evaluation and a nominal group techni-
que consensus conference with their consensus judgment
considered as gold standard. Sensitivity/specificity/
accuracy measures and the ability of the score to discri-
minate active versus inactive patients via the best cut-off
score were calculated by a receiver operating characteris-
tic (ROC) analysis.
Results
Consensus was achieved for 98/106 (92%) cases (39 FMF,
35 CAPS, 14 TRAPS and 10 MKD) with 26 patients
declared as having inactive disease and 72 active disease.
The median total AIDAI score was 14 (range = 0-175).
An AIDAI cut-off score ≥ 9 discriminated active versus
inactive patients, with sensitivity/specificity/accuracy of
89%/92%/90% respectively and an area under the curve
of 98% (95%CI=96%>100%).
Conclusion
The AIDAI score is a valid and simple tool for the
assessment of disease activity in FMF/MKD/ TRAPS/
CAPS This tool is easy to use in clinical practice and has
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